VPHIF VALEO PHARMA INC
- 0.070000
- -0.001600-2.23%
VALEO PHARMA INC News
Valeo Pharma Shareholders Endorse Management
Valeo Pharma Inc (TSE:VPH) has released an update.
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
Stocks in Play: Valeo Pharma Inc.
Valeo Pharma Reports Q1 Results
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST
Analysts Just Shaved Their Valeo Pharma Inc. (TSE:VPH) Forecasts Dramatically
It's Down 29% But Valeo Pharma Inc. (TSE:VPH) Could Be Riskier Than It Looks
Valeo Pharma Reports Q2 Results
Valeo Pharma Sees Q2 Revenue Above Estimates
Valeo Pharma to Webcast Live at VirtualInvestorConferences.com March 9th
MONTREAL, March 06, 2023 (GLOBE NEWSWIRE) -- Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE: VP2)) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, CEO, will present live
Valeo Pharma Reports Q4 Results
Great News for Valeo Pharma Inc. (TSE:VPH): Insiders Acquired Stock in Large Numbers Last Year
Valeo Pharma Raises Q4 Revenue Guidance
Valeo Inks Contract With Veru for COVID-19 Drug Sabizabulin
Valeo Pharma (OTCQB:VPHIF) said it signed a commercial services agreement with Veru for COVID-19 drug sabizabulin in Canada. Sabizabulin is an antiviral and anti-inflammatory drug being developed to t
Valeo Pharma Reports Q3 Results
Valeo Pharma press release (OTCQB:VPHIF): Q3 Revenue of $6.1M beats by $1.41M. Cash and liquidities of $27.7 million as at July 31, 2022
Analysis
Price Target
No Data
